AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18620563
Drug: Specialized addiction
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized addiction treatment plus treatment as usual
Trial: 18621618
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy plus lapatinib
Trial: 18621618
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy plus trastuzumab
Trial: 18621618
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy plus both lapatinib and trastuzumab
Trial: 18625666
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for > or = 4 h/night
Trial: 18625666
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for < 4 h/night
Trial: 18625762
Drug: High-dose lopinavir-ritonavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lopinavir-ritonavir (LPV/r) 400/100 mg/m(2) p.o. q12h without NNRTI
Trial: 18625762
Drug: High-dose lopinavir-ritonavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lopinavir-ritonavir (LPV/r) 480/120 mg/m(2) p.o. q12h with NNRTI
Trial: 18625762
Drug: Saquinavir (SQV)
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saquinavir (SQV) 750 mg/m(2) p.o. q12h added when LPV IQ <15
Trial: 18625762
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (LPV/r with or without SQV)
Trial: 18626272
Drug: Aripiprazole (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (20, 25, or 30 mg/d)
Trial: 18626272
Drug: Aripiprazole (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (maximum dose for cohort for 14 days)
Trial: 18635429
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin and rituximab
Trial: 18639220
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide implant insertion combined with phacoemulsification and intraocular lens implantation
Trial: 18643743
Drug: N-acetylcysteine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine and tigecycline catheter-lock solution for 14 days plus systemic antibiotic therapy
Trial: 18650621
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (interferon- and gemcitabine-based)
Trial: 18662932
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week for up to 20 weeks
Trial: 18668591
Drug: Rilonacept (IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (IL-1 Trap) 300 mg loading dose, followed by maintenance doses of 100 mg/week, with possible escalation to 160 mg/week and 320 mg/week.
Trial: 18668591
Drug: Rilonacept (IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (IL-1 Trap) 100 mg/week and higher doses (160 mg and 320 mg).
Trial: 18668591
Drug: Rilonacept (IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (IL-1 Trap) at higher doses (160 mg and 320 mg).
Trial: 18668653
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg by mouth every 8 hours for 6 weeks (initial 2-week titration).
Trial: 18668653
Drug: Pentoxifylline treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline treatment.
Trial: 18669874
Drug: Thalidomide (THAL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (THAL, 200 mg/d) with monthly pamidronate
Trial: 18669874
Drug: Low beta-2-microglobulin
RxNorm normalized name: Dianeal Low Calcium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low beta-2-microglobulin levels less than 2 mg/L
Trial: 18669874
Drug: Postsalvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postsalvage therapy
Trial: 18671877
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (10 g of gel containing 100 mg of testosterone)
Trial: 18673542
Drug: Non-invasive cardiac
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive cardiac imaging algorithm followed by evidence-based treatment (including CT calcium scoring, CT angiography, and DSMR testing)
Trial: 18681756
Drug: Citalopram, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram, starting at 20 mg/day, increased to 40 mg/day by weeks 2-4, and to 60 mg/day by weeks 4-6.
Trial: 18681756
Drug: Citalopram treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment.
Trial: 18682513
Drug: Cabergoline (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (1.3 +/- 1.3 mg/wk, treatment duration 12-60 months in 32%, >60 months in 68%)
Trial: 18682513
Drug: Cabergoline (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (cumulative dose above median)
Trial: 18682513
Drug: Cabergoline (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (cumulative dose below median)
Trial: 18682973
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Trial: 23226015
Drug: Treatment delay
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment delay
Trial: 18694333
Drug: Fixed-dose pyronaridine-artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose pyronaridine-artesunate combination (6:2, 9:3, 12:4 mg/kg tablet coformulations and 9:3 mg/kg granule coformulation) administered once daily for 3 days
Trial: 18694333
Drug: Fixed-dose pyronaridine-artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose pyronaridine-artesunate combination
Trial: 18694338
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine
Trial: 18694338
Drug: Two 90-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 90-microg doses in H5-naive subjects
Trial: 18698002
Drug: Allogeneic donor
RxNorm normalized name: Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells
DrugBank: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells (DB15731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic donor peripheral blood cells infusion after fludarabine and 200 cGy total body irradiation, with posttransplantation cyclosporine and mycophenolate mofetil.
Trial: 18698002
Drug: Uninterrupted administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uninterrupted administration of highly active antiretroviral therapy (HAART).
Trial: 18703791
Drug: Inter-alpha-trypsin inhibitor
RxNorm normalized name: Inter-alpha-trypsin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inter-alpha-trypsin inhibitor (IaI)
Trial: 18703791
Drug: Inter-alpha-trypsin inhibitor
RxNorm normalized name: Inter-alpha-trypsin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inter-alpha-trypsin inhibitor (IaI) deficiency
Trial: 18707849
Drug: Clarithromycin (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (1g within 1h of infusion for three consecutive days)
Trial: 18713945
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m2 per week)
Trial: 18722008
Drug: PTC124 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC124 at 16 mg/kg per day for 14 days (first cycle)
Trial: 18722008
Drug: PTC124 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC124 at 40 mg/kg per day for 14 days (second cycle)
Trial: 18726828
Drug: Leptin replacement
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin replacement treatment with recombinant methionyl human leptin for 24 months
Trial: 18728159
Drug: Outpatient 1-yr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient 1-yr intervention program based on exercise, behavior, and nutrition therapy
Trial: 18729192
Drug: PX-478 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-478 (20 mumol/L)
Trial: 18729192
Drug: PX-478 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-478 (50 mumol/L)
Trial: 18753661
Drug: 4-mm needle
RxNorm normalized name: NEEDLE,PEN 31G,4MM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mm needle for intramuscular injections
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in individuals with COPD (n=1888)
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in current smokers with COPD
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in former smokers with COPD
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in individuals without airflow obstruction (n=296)
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in non-smokers (n=201)
Trial: 18757456
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of serum CC-16 levels with age and gender in COPD subjects
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in individuals with GOLD stage II and III COPD
Trial: 18757456
Drug: Serum CC-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CC-16 levels in former smokers with reversible airflow obstruction
Trial: 18761748
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment in aggregate-containing tissues
Trial: 18761748
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment in aggregate-containing synovia
Trial: 18769731
Drug: Recombinant methionyl
RxNorm normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant methionyl human leptin (r-metHuLeptin) at physiologic replacement doses of 0.03 mg/kg/day
Trial: 18771667
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day Silibinin (IV) for 7 days
Trial: 18771667
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day Silibinin (IV) for 14 days
Trial: 18771667
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day Silibinin (IV) for 14 days
Trial: 18771667
Drug: 15 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/day Silibinin (IV) for 14 days
Trial: 18771667
Drug: 20 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day Silibinin (IV) for 14 days
Trial: 18776118
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II blockers added to ACE inhibitors
Trial: 18776118
Drug: Dual RAAS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAAS blockade (ACE inhibitors + Angiotensin II blockers)
Trial: 18776118
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors alone
Trial: 18779469
Drug: Dalteparin sodium,
RxNorm normalized name: dalteparin sodium,porcine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin sodium, 5000 IU once daily
Trial: 18781879
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of L-AmB alone (group A)
Trial: 18781879
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B)
Trial: 18781879
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 14 days (group C)
Trial: 18781879
Drug: 3.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D)
Trial: 18781879
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E)
Trial: 18784101
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus cetuximab (cisplatin or carboplatin plus fluorouracil with cetuximab at 400 mg/m² initially, then 250 mg/m² weekly)
Trial: 18784101
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin or carboplatin plus fluorouracil)
Trial: 18784623
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bevacizumab intravitreally in the worst eye
Trial: 18786301
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (VNS Therapy)
Trial: 18794207
Drug: Risperidone (0.5-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5-6 mg/day)
Trial: 18794207
Drug: Molindone (10-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molindone (10-140 mg/day, plus 1 mg/day of benztropine)
Trial: 18794456
Drug: Topical estradiol
RxNorm normalized name: estradiol Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estradiol 0.01%, 0.1%, 1%, or 2.5%
Trial: 18806079
Drug: Positive postnatal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive postnatal thyroid antibody tests
Trial: 18812445
Drug: Ambrisentan 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 2.5 mg qd for 4 weeks followed by 5 mg/d for 8 weeks
Trial: 18816386
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg IT morphine
Trial: 18816386
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg IT morphine
Trial: 18816386
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg IT morphine
Trial: 18816386
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 μg IT morphine)
Trial: 18816386
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 μg IT morphine)
Trial: 18816386
Drug: Control (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (300 μg IT morphine)
Trial: 18823688
Drug: Daily hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hemodialysis (DHD) 6 times/week with the NxStage System One device
Trial: 18823688
Drug: Thrice-weekly in-center
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly in-center hemodialysis (HD)
Trial: 18825363
Drug: Insulin-resistant (IR)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant (IR) individuals
Trial: 18825363
Drug: Insulin-sensitive (IS)
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive (IS) individuals
Trial: 18838471
Drug: High-risk cytogenetics
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk cytogenetics and/or at least two of the following: age >= 75 years, performance status >= 2, white cell count >= 50 x 10(9)/L
Trial: 18845370
Drug: eGFR(cysC) of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR(cysC) of 60 to 75 mL/min/1.73 m(2)
Trial: 18845370
Drug: eGFR(cysC) less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR(cysC) less than 60 mL/min/1.73 m(2)
Trial: 18852348
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (3 to 9 g per night in split doses over 6 weeks)
Trial: 18854394
Drug: Vorinostat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (200 mg twice daily for 2 weeks, followed by 1 week off therapy)
Trial: 18854394
Drug: Vorinostat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (200 mg twice daily)
Trial: 18854428
Drug: Off treatment
RxNorm normalized name: Wart-Off Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off treatment (no r-metHuLeptin)
Trial: 18856012
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h
Trial: 18856012
Drug: Standard-dose continuous
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 25 ml/kg/h
Trial: 18922099
Drug: ATRA (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA (22.5 mg/m2 twice daily for 2 days)
Trial: 18926148
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of statins and beta-blockers at discharge
Trial: 18931344
Drug: Obatoclax mesylate
RxNorm normalized name: mesylate
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax mesylate (GX15-070) administered at doses ranging from 3.5 to 14 mg/m² as a 1-hour infusion and from 20 to 40 mg/m² as a 3-hour infusion every 3 weeks.
Trial: 18931344
Drug: Obatoclax mesylate
RxNorm normalized name: mesylate
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax mesylate (GX15-070) administered at maximum tolerated dose (MTD) of 28 mg/m² over 3 hours every 3 weeks.
Trial: 18931344
Drug: Obatoclax mesylate
RxNorm normalized name: mesylate
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax mesylate (GX15-070) administered to 26 patients.
Trial: 18941347
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies using hormone agonists for treating uremic toxicity
Trial: 18942885
Drug: Intermittent, CD4-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent, CD4-guided antiretroviral treatment (ART) - Drug Conservation (DC)
Trial: 18945255
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day) for 48 weeks
Trial: 18952896
Drug: Folate-linked radioimaging
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate-linked radioimaging agent
Trial: 18955445
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily) with temozolomide (TMZ) (75 mg/m² daily) and radiotherapy (RT) (60 Gy)
Trial: 18955445
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily) with temozolomide (TMZ) (200 mg/m² daily for 5 days every 28 days)
Trial: 18955445
Drug: RT/TMZ (European
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT/TMZ (European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981)
Trial: 18955445
Drug: Nitrosourea-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrosourea-based chemotherapy (historical controls)
Trial: 18957506
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 microg twice daily for 15 d
Trial: 18971421
Drug: CD45 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD45 monoclonal antibodies (mAbs)
Trial: 18971421
Drug: CD45 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD45 monoclonal antibodies (mAbs) followed by EBV-specific CTL infusion
Trial: 18974373
Drug: Ipilimumab (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (0.1 to 3.0 mg/kg single infusion)
Trial: 18974373
Drug: Ipilimumab (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3.0 mg/kg single infusion)
Trial: 18976472
Drug: Immediate-release hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release hydromorphone
Trial: 18976472
Drug: Sustained-release hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release hydromorphone